Revised Credit Rating
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Ratings & Research has revised the outlook on Shilpa Medicare Limited and its material subsidiary Shilpa Pharma Lifesciences Limited to 'Positive' from 'Stable', while affirming the existing rating of IND A+ (with IND A1 for short-term). For Shilpa Medicare, this applies to fund-based working capital limits of INR 1.10 billion. For Shilpa Pharma Lifesciences, it covers working capital limits (reduced to INR 2,250 million from INR 2,850 million), non-convertible debentures (reduced to INR 750 million from INR 3,500 million), and a newly assigned proposed term loan of INR 750 million at IND A+/Positive. The outlook upgrade signals improved confidence in the group's credit profile, though the working capital and NCD facility sizes have been reduced from earlier levels.
A positive rating outlook upgrade is a favorable signal for shareholders, indicating the rating agency expects further improvement in the company's financial health. It may help lower borrowing costs and improve access to credit, though shareholders should note that overall debt facility sizes have shrunk for the subsidiary.